Silence Therapeutics Plc beat EPS estimates 67% of the time across 15 reported quarters (10 beats, 5 misses), averaging +2.2% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.32 | $-0.26 | +18.8% | Beat | |
| Q1 FY26 | $-0.33 | $-0.32 | +3.0% | Beat | |
| Q4 FY25 | $-0.32 | $-0.25 | +21.9% | Beat | |
| Q3 FY25 | $-0.40 | $-0.45 | -12.5% | Miss | |
| Q2 FY25 | $-0.27 | $-0.54 | -100.0% | Miss | |
| Q1 FY25 | not reported | $-0.60 | not reported | not reported | |
| Q4 FY24 | not reported | $0.27 | not reported | not reported | |
| Q3 FY24 | $-0.42 | $-0.63 | -50.0% | Miss | |
| Q2 FY24 | $-0.32 | $-0.42 | -31.3% | Miss | |
| Q1 FY24 | not reported | $-0.05 | not reported | not reported | |
| Q4 FY23 | $-0.25 | $-0.47 | -88.0% | Miss | |
| Q3 FY23 | $-0.56 | $-0.28 | +50.0% | Beat |
Back to SLN overview · SLN holders · SLN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.